ORIC financial statements
The full income statement, balance sheet, and cash-flow statement for Oric Pharmaceuticals Inc. (ORIC), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 143M+0.1% | 143M+29.0% | 111M+20.7% | 91.8M+16.4% | 78.9M+6.3% | ||
| Research & development | 110M-3.7% | 114M+33.9% | 85.2M+38.1% | 61.7M+8.5% | 56.9M+58.3% | |
| Selling, general & administrative | 33.2M+15.1% | 28.8M+12.6% | 25.6M+2.1% | 25.1M+14.0% | 22.0M+64.0% | |
| General & administrative | 33.2M+15.1% | 28.8M+12.6% | 25.6M+2.1% | 25.1M+14.0% | 22.0M+64.0% | |
| Operating income | -143M-0.1% | -143M-29.0% | -111M-20.7% | -91.8M-16.4% | -78.9M-6.3% | |
| Other non-operating income | 13.5M-10.0% | 15.0M+49.2% | 10.1M+281.2% | 2.65M+1595.5% | 156K-67.7% | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -129M-1.3% | -128M-27.0% | -101M-13.0% | -89.1M-13.2% | -78.7M-6.8% | |
| -$1.47+19.7% | -$1.83+6.6% | -$1.96+12.9% | -$2.25-8.7% | -$2.07 | ||
| EPS (basic) | -$1.47+19.7% | -$1.83+6.6% | -$1.96+12.9% | -$2.25-8.7% | -$2.07 | |
| Weighted-avg shares (basic) | 87.8M+25.9% | 69.7M+35.5% | 51.5M+29.7% | 39.7M+4.5% | 38.0M | |
| Weighted-avg shares (diluted) | 87.8M+25.9% | 69.7M+35.5% | 51.5M+29.7% | 39.7M+4.5% | 38.0M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 288M+10.0% | 262M+23.4% | 213M+1.0% | 210M-12.5% | 241M-18.9% | ||
| Cash & equivalents | 45.7M-23.1% | 59.4M+154.0% | 23.4M-65.0% | 66.8M-70.4% | 226M+188.1% | |
| Prepaid expenses | 6.98M+10.9% | 6.29M+42.6% | 4.41M+5.4% | 4.18M+18.1% | 3.54M+14.4% | |
| 409M+49.2% | 274M+8.8% | 252M+2.0% | 247M-17.2% | 299M-0.1% | ||
| Property, plant & equipment | 2.42M-17.4% | 2.92M+2.2% | 2.86M-12.0% | 3.25M+34.8% | 2.41M+21.8% | |
| Operating lease right-of-use | 6.66M-20.5% | 8.38M-8.4% | 9.14M-16.8% | 11.0M-6.9% | 11.8M | |
| Other non-current assets | 7.25M-19.2% | 8.97M-7.5% | 9.70M-15.8% | 11.5M-6.5% | 12.3M+3762.4% | |
| 20.4M-17.8% | 24.8M+21.4% | 20.5M+32.9% | 15.4M+1.6% | 15.2M+68.3% | ||
| Accounts payable | 3.82M+147.0% | 1.55M+64.0% | 944K-28.5% | 1.32M-30.0% | 1.89M+149.1% | |
| Accrued liabilities | 16.6M-28.8% | 23.3M+19.4% | 19.5M+38.7% | 14.1M+6.1% | 13.3M+60.9% | |
| Current lease liability | 3.33M+4.6% | 3.18M+15.7% | 2.75M+3.5% | 2.66M+38.1% | 1.93M | |
| 24.5M-20.9% | 31.0M+11.1% | 27.9M+12.5% | 24.8M-3.3% | 25.7M+178.3% | ||
| Long-term debt | — | — | — | — | 10.5M | |
| Non-current lease liability | 4.11M-33.4% | 6.17M-17.2% | 7.46M-21.0% | 9.44M-10.1% | 10.5M | |
| Operating lease liability (total) | 7.44M-20.5% | 9.36M-8.4% | 10.2M-15.6% | 12.1M-2.8% | 12.4M | |
| Other non-current liabilities | 4.11M-33.4% | 6.17M-17.2% | 7.46M-21.0% | 9.44M-10.2% | 10.5M+4701.4% | |
| 384M+58.1% | 243M+8.5% | 224M+0.8% | 222M-18.5% | 273M-5.8% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 11.0K+57.1% | 7.00K+16.7% | 6.00K+20.0% | 5.00K+25.0% | 4.00K+0.0% | |
| Additional paid-in capital | 1.08B+33.6% | 806M+22.3% | 659M+18.1% | 558M+7.7% | 518M+13.6% | |
| Retained earnings | -692M-23.0% | -563M-29.4% | -435M-30.1% | -334M-36.4% | -245M-47.3% | |
| Accumulated other comprehensive income | 786K+107.4% | 379K+46.9% | 258K+120.0% | -1.29M-1153.4% | -103K-232.3% | |
| Total liabilities & equity | 409M+49.2% | 274M+8.8% | 252M+2.0% | 247M-17.2% | 299M-0.1% | |
| Common shares issued | 98.5M+38.7% | 71.0M+29.4% | 54.9M+21.7% | 45.1M+14.4% | 39.4M+7.5% | |
| Common shares outstanding | 98.5M+38.7% | 71.0M+29.4% | 54.9M+21.7% | 45.1M+14.4% | 39.4M+7.5% | |
| Shares outstanding (cover) | 100M+41.3% | 71.0M+5.4% | 67.4M+49.4% | 45.1M+14.3% | 39.4M+7.5% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -111M+1.5% | -113M-31.5% | -85.7M-14.0% | -75.1M-26.2% | -59.5M-31.5% | ||
| Depreciation & amortization | 1.22M+10.2% | 1.11M+7.3% | 1.03M+6.8% | 966K+7.7% | 897K-7.5% | |
| Share-based compensation | 25.0M+23.9% | 20.2M+32.8% | 15.2M+5.3% | 14.5M+12.5% | 12.9M+143.5% | |
| -148M-768.7% | 22.1M+151.0% | -43.4M+60.3% | -109M-169.0% | 158M+173.4% | ||
| Capital expenditure | 712K-40.1% | 1.19M+39.9% | 849K-59.1% | 2.08M+121.3% | 939K+40.8% | |
| Free cash flow | -112M+1.9% | -114M-31.6% | -86.5M-12.1% | -77.2M-27.7% | -60.5M-31.7% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 400M+58.7% | 252M+5.3% | 239M+0.5% | 238M+242.0% | 69.6M-69.1% | |
| 245M+93.8% | 127M+47.7% | 85.7M+239.6% | 25.2M-48.7% | 49.1M-80.4% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 244M+95.5% | 125M+47.1% | 85.0M+240.0% | 25.0M-50.0% | 50.0M-81.6% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -13.7M-138.1% | 36.0M+182.9% | -43.4M+72.7% | -159M-207.5% | 148M+1481.8% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 821M+43.2% | 573M+14.2% | 502M+115.3% | 233M-59.8% | 580M-53.3% | |
| P/B | 2.1×-9.4% | 2.4×+16.2% | 2.0×+86.9% | 1.1×-48.9% | 2.1×-50.5% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: ORIC’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ORIC filings on SEC EDGAR → Not investment advice.